SBIR/STTR Research Award

Circulating Diagnostic Markers of Infectious Disease

Award identifier 0e4b12441cd994e70a57fd3fad74df2796c080e85815b4dc08bd8fe2598f4b9fAwarding agency Department of Defense · Office for Chemical and Biological Defense

Award amount

$149,504

Program and phase

STTR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Office for Chemical and Biological Defense
Recipient company
PATHOVACS INCORPORATED
Proposal award date
2018-09-20
Contract end date
2019-03-20
UEI
GAEYBFGAB1N9
Solicitation number
2018.0
Topic code
CBD18A-001

Research abstract

The focus of this STTR phase I component is on proof-of-concept studies demonstrating applicability of technical approaches for identificationof circulatory diagnostic markers for infectious disease. Therefore, the primary objective of this project is to determine feasibility of one suchtechnical approach called Proteomics-based Expression Library Screening (PELS), for identification of pathogen-derived proteins shed incirculation (shed proteins) during the process of infection. PELS is a proprietary, fully validated, highly sensitive platform proteome miningtool for discovery of the gamut of protein antigens expressed by any microbe during infection. Specifically, proof-of-concept will bedemonstrated by identifying a panel of proteins unique to virulent Brucella melitensis strain16 M that are shed in murine sera, collected atvarious time points following experiment infection of mice with the cognate pathogen. Phase II studies will involve application of this Phase Ivalidatedplatform technical approach to defining shed proteins in sera of patients infected with Brucella species and Rickettsia prowazekii,and in sera and cerebrospinal fluid of individuals infected with the Venezuelan Equine Encephalitis virus, followed by marker validation anddevelopment of prototype diagnostic assays. Phase III will involve partnered in vitro diagnostic instrument development and validationstudies for FDA approval, and commercialization.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2012–2022). Reported award amounts total $2,368,238. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Agriculture, Department of Defense, Department of Health and Human Services

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.